Lung Non-Small Cell Carcinoma — Trials

Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,749
Recruiting: 926
Ph III recruiting: 138
Growth YoY: +2.3%
Industry share: 44%
Top sponsor: AstraZeneca
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,045)

clinicaltrialsPublishedShowing 351–400 of 1,114 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07314216	Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma	recruiting	Phase 2	15	Hunan Cancer HospitalOTHER	1	Jul 8, 2026	clinicaltrials
NCT05424029	Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer	recruiting	—	200	Memorial Sloan Kettering Cancer CenterOTHER	1	Jul 7, 2026